The Forum was organised by the Industrial Politics and Innovations
Committee of Saint Petersburg and the Non-Commercial Partnership Medical
and Pharmaceutical Projects. XXI century. The event is supported by the
Ministry of Economic Development, the Ministry of Industry and Trade,
the Ministry of Health of the Russian Federation and the Government of
Saint Petersburg. It is the third time for the last three years when
GEROPHARM becomes a partner of such industry-important event.
A unique feature of the Life Sciences Invest Forum is its format, as
it includes round-tables, practical master-classes and partnering which
allows it becoming a platform for live business communications between
the main market participants every year. This year, the representatives
of GEROPHARM took part in several sections of the business and training
The General Director of GEROPHARM reported during the round-table discussion Innovative Infrastructure Development for High Tech Industries.
The event was attended by Vice-President of the Saint Petersburg
Industrial Policy and Innovations Committee Inna Shalyto; General
Director of the Russian Union of Industrialists and Entrepreneurs
Aleksandr Gabitov; General Director of Business Incubator Ingria Igor
Rozhdestvenskiy; Chief Executive Officer of FinnMedi Matti Eskola;
General Director of Non-Commercial Partnership Medical and
Pharmaceutical Projects. XXI century Dmitriy Chagin; Chairman of
Management Board of Medical and Pharmaceutical Projects. XXI century
Zakhar Golant and others.
During the discussion the round-table participants spoke about the problems and perspectives of development of urban innovation infrastructure, the idea of creation of an integrated cluster for Saint Petersburg and the Leningrad Region, the lack of the personnel having competence in priority industries and its training.
“The country faced an economic crisis in 2008, and it turned out that
the pharmacological industry became important. The creation of
pharmacological cluster in Saint Petersburg was started in 2009,” says
General Director of GEROPHARM, Group of Companies Pyotr Rodionov. “Here
in Petersburg, we have managed to get highly skilled specialists
involved who earlier leaved the country to work abroad. Petersburg is a
preferable place for those companies that start from the very beginning,
because here you can find a fundamental historical scientific base. In
spite of a number of difficulties related to the preferences we have
that, as we hope, are the temporary ones, we continue to work and are
sure that we will manage to monetize these preferences in the future.
This also concerns the preferences for the Russian manufacturers in
public procurement, as we often have to fight even for our internal
market although we are ready to enter the external one. There is no
doubt that the product manufacturers are growing, but we could make it
Summing up the round-table discussions, the speakers agreed that
Petersburg needs synergy of science, cumulative experience,
infrastructure and innovative ideas for further development and moving
to the next level.
HR-Director Natalia Skakunova took part in the round-table discussion
Practical Approaches to Search and Training of Personnel for the
Pharmaceutical and Biotechnological Industries. Natalia shared with
other participants GEROPHARM’s experience in the development and
implementation of student and graduate programs. GEROPHARM understands
that the future of the Russian pharmaceutics depends a lot on the
talented and initiative youth. That is why GEROPHARM supports joint
projects with leading specialized high educational institutions
including those initiated by the Saint Petersburg
Chemical-Pharmaceutical Academy (SPCPA).
Quality Director of GEROPHARM, group of companies Natalia Novichkova was a speaker of the section Integration of the Production Quality Control System as Part of Transfer to GMP Standards. Using the opening of the GEROPHARM-Bio plant (the beginning of the October this year) as an example, she presented to the audience, including the SPCPA students, the case with the information about the steps to be followed by a company and the rules to be used to integrate the modern good manufacturing standards at an enterprise.